Introduction
Chagas disease, also known as American trypanosomiasis, is a neglected tropical infection caused by the hemoflagellate protozoan parasite Trypanosoma cruzi [1] .
According to the World Health Organization, around 6-7 million people worldwide are estimated to be infected with this parasite, mostly in 21 Latin American countries [2] .
Moreover, Chagas disease is a global health problem mainly because of migration of people from endemic countries to the rest of the world [3] . Benznidazole and nifurtimox are the only drugs approved for the treatment of Chagas disease, which induce serious side-effects and have very limited efficacy, especially in the chronic phase of the disease [4] . Thus, studies focusing on the development of new therapeutic alternatives and on the identification of novel drug targets are still necessary.
Enolase (2-phospho-D-glycerate hydrolase, EC 4.2.1.11) is a key enzyme of the processes of glycolysis and gluconeogenesis and it catalyzes the reversible dehydration of 2-phosphoglycerate (2-PG) to phosphoenolpyruvate (PEP) in the presence of the metal ion magnesium (Mg 2+ ). Enolase is found in a wide variety of organisms ranging from bacteria to mammals including trypanosomatids [5] . Peptide mass fingerprinting allowed the detection of this enzyme in the different stages of T. cruzi life cycle, with a higher expression in trypomastigotes and amastigotes (forms present in the mammalian host) compared to epimastigotes (form present in the insect vector) [6] . Glycolysis and gluconeogenesis play crucial roles in the ATP supply and synthesis of glycoconjugates which are important for the viability and virulence of the human-pathogenic stages of T. cruzi, T. brucei and Leishmania spp. [7] , which are the etiological agents of the most important neglected diseases around the world. In addition to its metabolic importance, enolase has been proposed as a virulence factor in Leishmania spp. because of the enzyme ability to bind plasminogen [8] , Therefore, enolase constitutes an interesting enzyme target for the identification of drugs for Chagas' disease and also to other trypanosomatid-caused diseases.
Phosphonoacetohydroxamate (PAH) is a potent enolase inhibitor which has nanomolar values of IC 50 inhibitory activity against this enzyme from different species [9, 10] . The crystal structure of the T. brucei enolase (TbENO) with this inhibitor has already been determined, showing that PAH and the natural substrate PEP bind to the same residues in the structure [11, 12] . Recently, another highly potent enolase inhibitor, called SF2312 has been reported [13] . SF2312 is a phosphonate antibiotic of unknown mode of action produced by the actinomycete Micromonospora.
Moreover, TbENO has been validated as a drug target by RNA interference, which led to a negative effect on bloodstream trypomastigotes growth within 24 h and produced the death at 48 h. The same study also demonstrated that 80-85% reduction on enolase activity was enough for cell death to occur [14] . This evidence suggests that incomplete inhibition of this enzyme in vivo might prove sufficient for effective treatment.
Considering the relevance of enolase in trypanosomatids, in this work, we applied a combined virtual screening strategy, based on known ligands (2-PG, PEP, PAH and SF2312) and the protein target enolase, in order to find novel Trypanosoma cruzi enolase (TcENO) inhibitors from human-approved drug databases.
Methodology

Identification of the target protein
A screening in the TDR -Targets Database‖(v5) (http://tdrtargets.org/) was performed to obtain information about a potential drug target for Chagas disease [15] . The screening was restricted to T. cruzi genes coding for enzymes that produce a significant loss of fitness when absent or inhibited in the parasite or in related organisms. Resulting targets were then evaluated by bibliographical searching, and the TcENO was selected for identification of possible binders to the active site, as well as sequence and structural comparison with its homologues in humans, Trypanosoma brucei, and Leishmania Mexicana. Amino acid sequence analysis were performed using the T-Coffee multiple sequence alignment package [16] and structural alignment on PyMOL [17] .
Ligand-based virtual screening
Computational approaches for the identification of likely TcENO inhibitors started with a similarity-based search with molecules that experimentally bind to the active site of the protein, the enzyme substrates (PEP and 2-PG) and two previously characterized inhibitors (PAH and SF2312). The screening was performed on the Sweetlead database, that comprises about 10,000 drugs and isolates from traditional medicinal herbs [18] , using the software LiSiCA v1.0 (Ligand Similarity using Clique Algorithm) [19] , KCOMBU (K(ch)emical structure COMparison using the Build-up algorithm) [20] , and ShaEP (Molecular Overlay Based on Shape and Electrostatic 5Potential) v 1.1.2 [21] . The structures of the database were ordered with five different criteria: according to (I) the 2D and (II) 3D similarity using the LiSiCA software based on the Tanimoto similarity index [22] , (III) using the Ikcombu algorithm provided by the KCOMBU software, (IV) by shape and (V) electrostatic potential employing the ShaEP software. These algorithms were selected on the basis of the results obtained after doing the search with some known molecules, after discarding other algorithm that did not show the query molecule in the first position of the obtained lists. Following, for each of the characterized ligands, compounds that appeared between the first ten in at least three of the five ranking criteria were selected for further analysis.
Target-based virtual screening
The structural files of the molecules selected by similarity screening were then obtained from the ZINC database [23] . Preparation of the PDBQT files (Protein Data Bank, partial charge (Q), and atom type (T)) was performed using AutoDock Tools v1.5.6 [24] .
A search in the Protein Data Bank (PDB) [25] was carried to find the crystal structure of TcENO (PDB: 4G7F); but for being in apo conformation and lacking the residues ASTG(39-42), which are involved in the interaction with the phosphate groups of the ligands PEP and PAH, a structural model of the closed conformation was predicted by fragment assembly simulation using the server I-TASSER [26] . The model was validated by calculating its DOPE and GA414 scores with Modeller [27] , generating a Ramachandran plot in the online server Rampage [28] , and by redocking of PEP and PAH to see if the docking software was able to reproduce the poses of the ligands co-crystalized with the TbENO.
For molecular docking assays we used AutoDock 4.5 [29] , with a grid map of 50 x 58
x 44 points, spacing of 0.0375 nm, and centered on the position occupied by PEP in the TbENO crystal structure, surrounding the residues conforming the enzyme active site (Ala39, Ser40, Lys155, His156, Glu165, Asp243, Glu291, Asp318, Lys343, His371, Arg372, Ser373, and Lys394).
As enolase needs two dicationic ions in the active site to bind its substrates, magnesium ions were added to the PDBQT file of the receptor, according the coordinates of the magnesium ions found in the 2PTY pdb file. For each ligand we did 100 docking runs with the Lamarckian Genetic Algorithm, with a population size of 300, and 2.7x10 4 as the maximum number of generations, followed by conformational clustering of the obtained poses into groups with RMSD <0.2 nm. All the obtained docking poses were visually analyzed using PyMOL [17] , and rescored using the neural-network based scoring software NNScore v1 [30] .
Pharmacophore modeling
Structural alignments and pharmacophore modeling were performed using 
Molecular Dynamics
The poses with less free energy obtained from AutoDock 4.5 for PEP, etidronate and pamidronate were assessed by molecular dynamic (MD) simulations using GROMACS 5.0.5 [32] . For this, the topology of the TcENO (including the magnesium ions) was calculated using the GROMOS96 43a1 force field. The topology of the TcENO in complex with the ligands was obtained by merging the topology obtained for each ligand from the PRODRG server [33] , and embedded in the TcENO topology file. Water molecules and ions were added to each TcENO-ligand system in a dodecahedral solvation box, using the SCP water model. After energy minimization of the system, restraints were applied to the position of the protein and the ligand.
The system was then heated to 300 K at constant volume (NVT) during 50 ps, using a modified Berendsen thermostat with a temperature coupling time constant (τt) of 0.1 ps; followed by 50 ps of pressure equilibration (NPT) with isotropic Berendsen barostat at 1.0 bar of pressure at a time constant (τp) of 2.0 ps. Restraints were removed and the MD production run was extended for 50 ns at a pace of 2 fs, recorded every 10 ps for further analysis.
Periodic boundaries conditions were removed from the resulting trajectories to further align them using the RMSD visualizing tool on VMD [34] , fitting the trajectories to the backbone of the protein. The snapshots were then visually analyzed and RMSD was calculated for the protein and the ligands. On VMD, the Hbonds formed across the trajectories between the ligands and the protein were obtained for all the trajectories, setting a 0.35 nm bond distance and angle of 30°.
The residues with a distance to the ligand <0.5 nm were considered for contact counting with ‗gmx mindist', and interaction energy calculations with ‗gmx energy'.
The binding free energies of the simulated complexes were calculated with the tool GMXPBSA 2.1 [35] on 100 frames extracted from the last 30 ns of simulation.
Principal component analysis (PCA) was performed on the same time lapse of the trajectories, using the gromacs tools ‗gmx covar' and ‗gmx anaeig', followed by a free energy landscape (FEL) generated for the projection of the first two principal components (PC1 and PC2) using ‗gmx sham' and ‗xpm2ps'.
Results and Discussion
Target analysis
A screening restricted to T. cruzi genes coding for enzymes which inhibition or deletion also produce a significant loss of fitness in bloodstream forms of T. brucei (no information is available for T. cruzi) using the TDR -Targets Database‖ (v5) to retrieve potential drug targets was performed. The enzyme TcENO was present among the group of T. cruzi genes resulting from the screening. In T. brucei, the knock-out of this this enzyme also produced a validated loss of fitness in the bloodstream and procyclic forms of the parasite, in addition to affect the differentiation between the procyclic to bloodstream forms. The enolase is also indicated as a known druggable target in humans in its three isoforms. A multiple alignment between the TcENO, TbENO, LmENO, and the three human enolases (HsENO1, 2, and 3) shows that residue Lys155, conserved in the enzyme sequence of all three trypanosomatids evaluated, is replaced by a serine in the human homologues (Online Resource 1). This residue belongs to a very flexible loop on the active site, being able to move towards the cavity or accommodating away from it [36] , altogether pointing the exploitability of this residue in the design of drugs specific to trypanosomatid enolases. These results indicate that Tc ENO meets the requirements to be an excellent drug target: it is essential in all stages of the parasite, including the processes of differentiation between them; it is druggable, as other enolases have known inhibitors; it has differences with the human homologue; and its enzymatic activity is easy to measure.
Similarity screening.
The first step of the screening for putative TcENO inhibitors was a ligand-based strategy using the enzyme substrates (2-PG and PEP, Fig.2a ) and previously characterized inhibitors (PAH and SF2312, Fig.2b ) as query structures. The Sweetlead database was screened using three different similarity search software with a total of five different algorithms, as detailed under -Methodology‖. For each query molecule, the top ten scored compounds that were detected at least by three algorithms were chosen for further analysis. Using these criteria eight possible inhibitors of the TcENO were obtained; six of them of medical use and two human metabolites. These compounds were: I) etidronate and II) pamidronate, two bisphosphonates used to treat Paget's disease of bone and to prevent and treat heterotopic ossification; III) fosfomycin, an antibiotic used to treat infections of the urinary tract; IV) acetohydroxamate, used to lower the level of ammonia in urine in some types of urinary infections; V) triclofos, a sedative drug used for treating insomnia, VI) aminohydroxybutyrate, an anticonvulsant which is used for the treatment of epilepsy, and the human metabolites VII) phosphoserine and VIII) glycerol-3-phosphate (Fig.2c ). The two metabolites were excluded from further evaluation.
TcENO structure modeling
In the production of the 3D model for the TcENO, the I-TASSER simulations converged in a single structure, which signals a good quality of the model. To further assessing the quality of the model we used various approaches. The quality score that I-TASSER gives for the models it produces, the C-score, was 1.77 for the TcENO; this score ranges from -5 to 2, where the best score being 2. The Ramachandran plot shows only a residue (Arg400) falling in the outlier region, with every other residue inside the favored or allowed regions (Online Resource 2). The GA341 and the DOPE scores calculated with Modeller were respectively 1.0 and -15.55; the later ranges from 0.0 to 1.0, where values nearest or equal to 1.0 signal a good quality, while the former represents the energy of the protein, where lower values are assigned to better quality models. Altogether, these metrics show that the predicted structure has an overall good quality. Fig.3 shows the generated poses for etidronate, pamidronate, PAH, and PEP, with the TcENO residues predicted to form h-bonds with each ligand. For PEP and PAH all the predicted h-bonds are listed in the PDB entries for their complexes with TbENO. All four compounds share a phosphate motif, which appears interacting in the same manner with the residues Ala39, Ser40, Arg372, Ser373, and one of the magnesium ions, pointing the importance of these interactions for the binding mode, suggesting any future drug designed to inhibit TcENO should retain highly electronegative atoms in this position. The remaining phosphate in etidronate and pamidronate is shown interacting with Arg372, Lys3443, Lys394, and the two magnesium ions, in a similar fashion as the carboxyl group in PEP, and in PAH the hydroxyl and the carbonyl groups, implying the necessity of electronegative groups in that space for the ligands to bind. The hydroxyl group in etidronate in was located towards the magnesium ions and residue Gln164, Glu165, and Glu208; while the methyl group was pointing towards Lys343 and Arg372. For pamidronate, the pose was similar to that of etidronate, with the distinct amine in the direction of Lys343, Gln165, and Glu208; extending towards His371.
Molecular docking
Pharmacophore model
A pharmacophore was constructed using the structures that bind into the active site 
Evaluation of docking poses
In order to describe in more detail the possible mode of interaction of etidronate and pamidronate with the protein, as well as to address the flexibility of the receptor in the interaction, we performed MD simulations on the apo form of the protein, and in complex with both ligands.
Root Mean Squared Deviation
Simulations of 100 ns were run with Gromacs for TcENO in apo form. The backbone RMSD for was lower than 0.3 nm, achieving stability after 10 ns, so for the complexes with ligands we did the simulations for 50 ns.
MD for the protein complex with PEP, etidronate, and pamidronate resulting from the molecular docking also had backbone RMSD values (Fig.4a ) lower than 0.3 nm. For PEP the mean value between 20 and 50 ns was lower than the apo form, as expected for a protein stabilized by interactions with its ligand. For etidronate the value was even lower, which could mean the interactions with this ligand allows for less conformational changes of the protein during the simulation. In the case of the pamidronate complex the backbone RMSD is similar to that of PEP up to 25 ns, when it increases reaching values similar to that of the apo form, suggesting an increase in the protein flexibility after this point in the simulation.
RMSD of the ligands (Fig.4b ) are lower than 0.2 nm for PEP and etidronate, and show less variation for etidronate than PEP, suggesting again the interactions between the former and TcENO allow for less flexibility than for the former. For pamidronate the ligand RMSD was higher than for the other two, and it shows an increase after 30 ns to values higher than 0.3 nm, indicating big conformational changes that in addition to the increase in flexibility of the protein might be the product of the loss of the interactions predicted by the molecular docking. This was confirmed upon visual examination of the frames, where pamidronate starts with both phosphate groups interacting in the same pocket as etidronate and the amine wobbling, followed by a motion of the whole molecule towards a more distal position in the pocket. In the case of pamidronate H-bonds were less frequent, with the backbone NH of residues Ala39, Ser40 and Ser373 establishing such interactions with the ligand in 38%, 14% and 12% of the frames, respectively. His371 and Arg372 side chains had H-bonds with pamidronate in 11% of the simulation, and many other residues establishing H-bonds in less than 10% of the run.
H-bonds
Binding energy and residue interaction
Binding free energy of the complexes with the ligands was calculated with GMXPBSA 2.0 ( Table 1) . TcENO-PEP complex had the lowest binding ΔG, with a predominant electrostatic contribution. For TcENO-etidronate the binding energy was 2.5 times higher but still negative, while in Tc ENO-pamidronate the binding energy was around zero, as a result highly positive polar contribution, which can be attributed to the NH 2 group for being the only polar substituent in pamidronate that is not present in etidronate. The low binding energy for the pamidronate is consistent with the increase in RMSD of the ligand and its translocation inside the active site, signaling the loss of the interactions predicted by the molecular docking.
To address the individual contribution of residues to the interaction we summed the Coulombic and Lennard-Jones energies that were in contact with the ligands in more than 50% of the analyzed frames. As listed in Table 2 , the residues with the lowest interaction energy with PEP are all noted in the PDB entry of 2PTY as the involved on the binding, which validates the capability of the model to predict the experimental binding mode. Regarding the bisphosphonates, the interaction energies with pamidronate are lower compared to etidronate, and both of them lower than PEP.
Free Energy Landscape
The projections of the first (PC1) and second (PC2) eigenvectors were used to calculate the Free Energy Landscape (FEL) (Fig.6) , with a color code where deeper blue color indicate wells of low free energy, where the protein conformation is more stable. The complexes TcENO-PEP (Fig.6b) and TcENO-etidronate (Fig.6d ) had the most metastable conformational states, with local free energy wells distributed in four to five regions during the 50 ns simulation, while apo TcENO (Fig.6a) and TcENOpamidronate ( Fig.6c ) had just two to three metastable conformations. In all the simulations the low energy configurations were explored several times by the protein. This results further confirm that binding to etidronate and PEP stabilizes the protein, while the complex with pamidronate has a stability comparable with the apo conformation.
Conclusions
Enolase has been identified as a promising target in the search of drugs to treat Chagas disease, as well as other trypanosomatid caused diseases, for the essential role it plays in the energetic metabolism of the parasite and processes of transition between forms in its life cycle. In this work, we use previously characterized ligands as templates in the search of new possible inhibitors by similarity screening in a database comprising many approved drugs for its use in humans. After discarding metabolites retrieved in the search, a total of 6 compounds were used for molecular docking assays in order to predict their ability of binding to the active site of TcENO, Table 2 Percentage of frames with contacts and interaction energy (IE) between the ligands and TcENO amino acid residues with more than 50% of contacts Figure 1 . Amino acid multiple alignment of the enolases from T. cruzi, T. brucei, L. mexicana, and the three human enolases (ENO1, ENO2, and ENO3). Figure S3 . Pharmacophore mapping. A) Pharmacophore designed using the structures in common of the experimental binders of enolase and those predicted to bind in the molecular docking. Five H-bond acceptors are indicated as balls and a negative ionizable region as an asterisk (see reference). B) The structure of etidronate and pamidronate inside the pharmacophore representation. C) Table comparing the pharmacophore structures shared by the different compounds. D) Structures of the different compounds indicating the H-bond acceptors (HBA) and the negative ionizable groups (NI).
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